Silo Pharma (SILO) Liabilities and Shareholders Equity (2010 - 2026)

Silo Pharma has reported Liabilities and Shareholders Equity for 14 years, with the latest figure at $7.0 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 18.95% year-over-year to $7.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.7 million (down 7.54% YoY) and the FY2025 annual result came in at $7.6 million, up 2.61% from the prior year.
• Liabilities and Shareholders Equity declined to $7.0 million in Q1 2026 per SILO's latest filing, from $7.6 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $13.0 million in Q3 2022 and troughed at $5.9 million in Q1 2025.
• A 5-year average of $8.6 million and a median of $8.0 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity jumped 80.75% in 2022, then slumped 37.03% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $11.6 million in 2022, then slumped by 33.47% to $7.7 million in 2023, then declined by 4.32% to $7.4 million in 2024, then increased by 2.61% to $7.6 million in 2025, then retreated by 7.72% to $7.0 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $7.0 million, $7.6 million, and $6.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.